FDA Must Lift "Limbo" Over Trials In Supplement Development - Caucus
This article was originally published in The Tan Sheet
Executive Summary
FDA should move dietary supplement firms out of "limbo" when it comes to the rules for using scientific studies in developing new products, industry supporters in the House say